ANN ARBOR
Saturday, June XX
X:XX pm
REGISTER NOW!

BALTIMORE
Tuesday, June XX
X:XX pm
REGISTER NOW!

BOSTON
Wednesday, July XX
X:XX pm
REGISTER NOW!

CHICAGO
Saturday, July XX
X:XX pm
REGISTER NOW!

LOS ANGELES
Monday, July XX
X:XX pm
REGISTER NOW!

NEW YORK
Friday, July XX
X:XX pm
REGISTER NOW!

PHILADELPHIA
Tuesday, August XX
X:XX pm
REGISTER NOW!

SACRAMENTO
Saturday, August XX
X:XX pm
REGISTER NOW!

SAN FRANCISCO
Wednesday, August XX
X:XX pm
REGISTER NOW!

WASHINGTON DC
Friday, August XX
X:XX pm
REGISTER NOW!

Topics

• Real World nAMD Management: Case Presentations
• Real World DME Management: Case Presentations

Target Audience

The intended audience for this activity is retina specialists, comprehensive ophthalmologists, and other healthcare professionals involved in the management of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Recognize the need for novel treatments and regimens that can improve visual outcomes in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
• Assess currently available injectable treatment options and protocols for their ability to lengthen treatment intervals and provide durability of response in patients with nAMD and DME.
• Incorporate durable injectable treatment regimens that offer enhanced efficacy and safety in patients with nAMD and DME.

Overview

Placeholder Text: Real-world outcomes of patients with retinal diseases treated with intravitreal anti-vascular endothelial growth factor (VEGF) therapies are often suboptimal when compared to the results demonstrated in pinnacle clinical studies. The discrepancies in outcomes have in part been attributed to patients receiving fewer than the recommended number of anti-VEGF injections, as well as patients discontinuing therapy due to treatment burden associated with frequent dosing schedules. New imaging techniques that allow for better monitoring of therapy response, along with the refinement of treatment protocols that extend the interval between treatment dosing, have the potential to reduce treatment burden while providing optimal visual outcomes. In this 4-part webinar series, experts in the field will provide guidance on the management of diabetic retinopathy (DR), diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD), and retinal vein occlusion (RVO). Topics covered include utilizing recent advances in imaging to monitor treatment response in patients with retinal diseases, identification of baseline factors that help predict anti-VEGF therapy outcomes, and evaluation of anti-VEGF treatment outcomes in clinical practice. Furthermore, challenging real-world cases will be presented, allowing for incorporation of the content into clinical practice.